BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1052 related articles for article (PubMed ID: 16010295)

  • 1. Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation.
    Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
    Cell Mol Biol Lett; 2005; 10(2):305-19. PubMed ID: 16010295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dexamethasone down-regulates cAMP-phosphodiesterase in human osteosarcoma cells.
    Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
    Biochem Pharmacol; 2005 Jan; 69(2):267-75. PubMed ID: 15627479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.
    Moon E; Lee R; Near R; Weintraub L; Wolda S; Lerner A
    Clin Cancer Res; 2002 Feb; 8(2):589-95. PubMed ID: 11839681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of substrate specificity determinants in human cAMP-specific phosphodiesterase 4A by single-point mutagenesis.
    Richter W; Unciuleac L; Hermsdorf T; Kronbach T; Dettmer D
    Cell Signal; 2001 Mar; 13(3):159-67. PubMed ID: 11282454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
    Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
    Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of PDE4 structure on inhibitor selectivity across PDE families.
    Ke H
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S24-7. PubMed ID: 15224132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells.
    Verghese MW; McConnell RT; Lenhard JM; Hamacher L; Jin SL
    Mol Pharmacol; 1995 Jun; 47(6):1164-71. PubMed ID: 7603456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of specific phosphodiesterase isoenzyme inhibitors on bovine oocyte meiotic maturation.
    Thomas RE; Armstrong DT; Gilchrist RB
    Dev Biol; 2002 Apr; 244(2):215-25. PubMed ID: 11944932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.
    Growcott EJ; Spink KG; Ren X; Afzal S; Banner KH; Wharton J
    Respir Res; 2006 Jan; 7(1):9. PubMed ID: 16423283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3.
    Feijge MA; Ansink K; Vanschoonbeek K; Heemskerk JW
    Biochem Pharmacol; 2004 Apr; 67(8):1559-67. PubMed ID: 15041473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PDE4 and PDE5 regulate cyclic nucleotides relaxing effects in human umbilical arteries.
    Santos-Silva AJ; Cairrão E; Morgado M; Alvarez E; Verde I
    Eur J Pharmacol; 2008 Mar; 582(1-3):102-9. PubMed ID: 18234184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitric oxide-mediated regulation of connexin43 expression and gap junctional intercellular communication in mesangial cells.
    Yao J; Hiramatsu N; Zhu Y; Morioka T; Takeda M; Oite T; Kitamura M
    J Am Soc Nephrol; 2005 Jan; 16(1):58-67. PubMed ID: 15537869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profiling of functional phosphodiesterase in mesangial cells using a CRE-SEAP-based reporting system.
    Zhu Y; Yao J; Meng Y; Kasai A; Hiramatsu N; Hayakawa K; Miida T; Takeda M; Okada M; Kitamura M
    Br J Pharmacol; 2006 Jul; 148(6):833-44. PubMed ID: 16751794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of 3',5' cyclic nucleotide phosphodiesterase activity in Y79 retinoblastoma cells: absence of functional PDE6.
    White JB; Thompson WJ; Pittler SJ
    Mol Vis; 2004 Oct; 10():738-49. PubMed ID: 15480303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity.
    Rose RJ; Liu H; Palmer D; Maurice DH
    Br J Pharmacol; 1997 Sep; 122(2):233-40. PubMed ID: 9313930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts.
    Marko D; Romanakis K; Zankl H; Fürstenberger G; Steinbauer B; Eisenbrand G
    Cell Biochem Biophys; 1998; 28(2-3):75-101. PubMed ID: 9515161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carboxyamidotriazole: a novel inhibitor of both cAMP-phosphodiesterases and cGMP-phosphodiesterases.
    Guo L; Luo L; Ju R; Chen C; Zhu L; Li J; Yu X; Ye C; Zhang D
    Eur J Pharmacol; 2015 Jan; 746():14-21. PubMed ID: 25446933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple cyclic nucleotide phosphodiesterases in human trabecular meshwork cells.
    Zhou L; Thompson WJ; Potter DE
    Invest Ophthalmol Vis Sci; 1999 Jul; 40(8):1745-52. PubMed ID: 10393044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-time monitoring of phosphodiesterase inhibition in intact cells.
    Herget S; Lohse MJ; Nikolaev VO
    Cell Signal; 2008 Aug; 20(8):1423-31. PubMed ID: 18467075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.